Verified Rigor RecordRigor Reviewed

Rigor-Reviewed Manuscript

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

Name: Verified Rigor Record — Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.
Item: Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.
Rating: 88
Author: Αlpha¹

Peng Z, Zhang Y, Xu H, Yang Y, Yang M, Zhang M, Cheng Y, Chen X, Pan Y, Wang F, Li Q, Xu N, Liu L, Gu K, Xiao J, Zhang R, Zhao Q, Chen J, Lin L, Chen Y, Deng Y, Cai S, Bai B, Wang Y, Shen L

Paper source

Open DOI

Embed this Rigor badge

Αlpha¹ Verified Rigor Record — Rigor score 88/100 (Exceptional strength of evidence) for “Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.”

Links back to this verified record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · July 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

WARN

Warnings to address · Interventional Study

Eight dimensions — click a segment for details

Critical

High-priority

Model-reported confidence: highReviewer agreement: moderateEngine: 7.7.0Source: full text

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted phase 3 trial with a clear design, rigorous statistical analysis, and transparent reporting. The main weaknesses are incomplete reporting of key resources (drug manufacturers, antibody catalog number) and demographic variables (weight, race/ethnicity), and the analysis code is only in a supplemental file rather than a version-controlled repository.

Both reviewers (AI) evaluated the full text. The verification components checked 26 references (none retracted or not found), 2 recomputed statistics (both consistent), and 1 data link (live). The claim audit found no under-evidenced claims. The copyedit pass flagged 8 minor consistency/clarity issues.

9 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 2 tests: 2 consistent, 0 inconsistent, 2 via agent-written checks.

Rigor

Eight Dimensions5 pass · 3 warn

9 major claims2 partial7 supported

The introduction cites prior epidemiological data, clinical standards, and key trials (e.g., CheckMate 649, KEYNOTE-859). It provides a clear rationale for investigating PD-1/VEGFR2 synergy and for comparing maintenance strategies. Limitations of prior work (e.g., lack of phase 3 data on maintenance) are explicitly noted and addressed by the study design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The study clearly establishes its scientific premise with a well-referenced background, logical rationale, and acknowledgment of prior research gaps.

Evidence

direct quote[Introduction, paragraphs 3-5]

“Preclinical studies have shown that concurrent blockade of programmed death-1 and vascular endothelial growth factor receptor 2 may produce synergistic antitumour effects.”

direct quote[Introduction, paragraph 5]

“These findings raised the hypothesis that introducing an antiangiogenic agent during maintenance might enhance or prolong the benefits of immune checkpoint inhibitor based initial treatment, but whether such intensification provides meaningful clinical benefit beyond immune checkpoint inhibitor maintenance alone, given the potential for additional toxicity, is unknown.”

direct quote[Introduction, paragraph 3]

“However, the optimal maintenance strategy and the potential role of treatment intensification during maintenance remain uncertain, and prospective phase 3 data directly comparing immune checkpoint inhibitors based maintenance approaches are lacking.”

PASSReviewer 2· 95% conf

The study clearly establishes its scientific foundation by citing prior research, providing a logical rationale, and acknowledging limitations of prior work.

Evidence

direct quote[Introduction, paragraph 3]

“At the time our trial was designed, phase 3 evidence supporting immune checkpoint inhibitors plus chemotherapy over chemotherapy alone had not yet been established.”

direct quote[Introduction, final paragraph]

“We conducted a multicentre, randomised, phase 3 trial to build on these findings and to investigate the evolving role of programmed death 1 inhibitors as initial treatment.”

direct quote[Discussion, 'Strengths and limitations of this study']

“the protocol specified maintenance phase with two different camre based strategies allowed us to generate comparative data on the role of adding a vascular endothelial growth factor receptor 2 inhibitor to maintenance immunotherapy, an area for which phase 3 evidence has been lacking.”

PASSReviewer 3· 95% conf

The paper establishes a strong scientific foundation by citing prior research, providing a clear rationale, and addressing limitations of prior work.

Evidence

direct quote[Introduction, paragraph 3]

direct quote[Introduction, paragraph 4]

“Preclinical studies have shown that concurrent blockade of programmed death-1 and vascular endothelial growth factor receptor 2 may produce synergistic antitumour effects.”

paraphrase[Introduction, paragraph 5]

“The study builds on a phase 2 trial and aims to answer whether adding apatinib to camrelizumab maintenance improves outcomes compared with camrelizumab alone.”

Randomization used a centralized interactive web response system with block randomization (block size 6) and stratification by ECOG performance status, peritoneal metastasis, and PD-L1 CPS. The open-label design is stated with a rationale (primary endpoint OS is objective). Sample size calculations are detailed with assumptions for HR, power, and alpha. Eligibility criteria are clearly defined, and the primary analysis population (patients receiving ≥1 dose of study drug) is pre-specified.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The study design is rigorous with a randomized, multicentre structure, stratified randomization, pre-specified power analysis, and well-defined eligibility criteria.

Evidence

direct quote[Methods, Randomisation and masking]

“Patients were randomly assigned through a centralised interactive web response system using block randomisation (block size of six), stratified by Eastern Cooperative Oncology Group performance status (0 v 1), presence of peritoneal metastasis (yes v no), and PD-L1 combined positive score (>1 v ≤1).”

direct quote[Methods, Randomisation and masking]

“This was an open label study: neither investigators nor patients were masked to treatment allocation.”

direct quote[Methods, Statistical analysis]

“We estimated that 340 deaths would provide 88% power to detect a hazard ratio of 0.71 (median overall survival 16.2 v 11.5 months) in the PD-L1 positive population, and 576 deaths to provide 91% power to detect a hazard ratio of 0.76 (median overall survival 15.1 v 11.5 months) in the overall population.”

PASSReviewer 2· 95% conf

The study design is rigorous, with clear randomization, an open-label design with rationale, pre-specified power analysis, and detailed inclusion/exclusion criteria.

Evidence

direct quote[Methods, Randomisation and masking]

“Patients were randomly assigned through a centralised interactive web response system using block randomisation (block size of six), stratified by Eastern Cooperative Oncology Group performance status, presence of peritoneal metastasis, and PD-L1 combined positive score.”

direct quote[Methods, Randomisation and masking]

“This was an open label study: neither investigators nor patients were masked to treatment allocation.”

direct quote[Methods, Statistical analysis]

PASSReviewer 3· 90% conf

The study design is robust with adequate randomization, power analysis, and inclusion/exclusion criteria, though the open-label design lacks a rationale.

Evidence

direct quote[Methods, Randomisation and masking]

“This was an open label study: neither investigators nor patients were masked to treatment allocation.”

direct quote[Methods, Statistical analysis]

“In the final design, we applied a fixed sequence testing strategy: overall survival was first tested between camre+CAPOX followed by camre+apa and CAPOX in the PD-L1 positive population, and if statistically significant, subsequently in the overall population, both at a one sided α of 0.025.”

Table 1 reports sex and age (median, IQR). Health status is reported via ECOG performance status and disease characteristics. However, weight is not reported, and race/ethnicity or comorbidities are not mentioned (though the study was conducted in China). This results in only one of three applicable sub-criteria being fully adequate.

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthINADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 70% conf

Sex, age, and clinical health status are well-reported, but race/ethnicity is not explicitly tabulated; the study is in China, so ethnicity is implied.

Evidence

direct quote[Table 1]

“Sex: Male: 250 (71.0), Female: 102 (29.0)”

direct quote[Table 1]

“Median (IQR) age (years) 62 (55-67)”

absence[Table 1 and Methods]

Race/ethnicity is not explicitly reported in a demographic table; only implied by study location (China).

WARNReviewer 2· 85% conf

Sex and age are reported, but weight and comprehensive demographics (race/ethnicity, comorbidities) are not reported, limiting full characterization of the study population.

Evidence

direct quote[Table 1, Baseline characteristics]

“Sex: Male 250 (71.0), Female 102 (29.0); Median (IQR) age (years): 62 (55-67)”

absence[Table 1]

Weight not reported.

absence[Table 1]

Demographics (race/ethnicity, comorbidities) not reported.

WARNReviewer 3· 80% conf

Sex and age are reported, but weight and comprehensive health status (e.g., comorbidities) are not reported, and race/ethnicity is not provided.

Evidence

direct quote[Results, Table 1]

“Median (IQR) age (years): 62 (55-67) ... Sex: Male 250 (71.0), Female 102 (29.0)”

absence[Results, Table 1]

Weight is not reported.

absence[Results, Table 1]

Race/ethnicity is not reported.

The paper states that the protocol was approved by the ethics committee at each participating centre (referenced in supplementary table S1). Written informed consent was obtained from all participants. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. These satisfy all applicable criteria.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval from each participating centre, written informed consent from all participants, and adherence to Declaration of Helsinki and GCP are explicitly stated.

Evidence

direct quote[Ethics statements]

“The study protocol and all amendments were approved by the ethics committee at each participating centre (see supplementary table S1) and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.”

direct quote[Methods, Study design and patients]

“Written informed consent was obtained from all participants before enrolment.”

PASSReviewer 2· 95% conf

Ethical approval, informed consent, and regulatory compliance are clearly reported, meeting all applicable criteria.

Evidence

direct quote[Ethics statements]

direct quote[Methods, Study design and patients]

“Written informed consent was obtained from all participants before enrolment.”

PASSReviewer 3· 95% conf

Ethical approval, informed consent, and regulatory compliance are adequately reported.

Evidence

direct quote[Ethics statements]

direct quote[Methods, Study design and patients]

“Written informed consent was obtained from all participants before enrolment.”

Camrelizumab, apatinib, capecitabine, and oxaliplatin are described with doses but not with manufacturer/source. The PD-L1 antibody (E1L3N clone) is named without vendor or RRID. SAS version 9.4 is reported adequately. The analysis code is provided in a supplemental file, not a version-controlled repository. These gaps make the reporting of biological/chemical resources incomplete.

Sub-criteria

mycoplasma testingN/A

reagents identifiedINADEQUATE

organisms identifiedN/A

antibodies identifiedINADEQUATE

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 85% conf

The investigational drugs and PD-L1 antibody are named but lack vendor, catalog numbers, or lot numbers; SAS version is provided, but analysis code is only in supplemental file, not a public repository.

Evidence

direct quote[Methods, Procedures]

“A central laboratory (Shanghai Xiawei Biotechnology, Amoy Diagnostics, Shanghai, China; certified by the College of American Pathologists) evaluated PD-L1 combined positive score using an immunohistochemistry assay with the E1L3N antibody clone.”

direct quote[Methods, Procedures]

“Patients assigned to the camre+CAPOX followed by camre+apa group received camrelizumab (200 mg intravenously every three weeks) plus CAPOX (capecitabine 1000 mg/m² orally twice daily on days 1-14 of each 21 day treatment cycle, and oxaliplatin 130 mg/m² intravenously on day 1 of each cycle) for four to six cycles, followed by camrelizumab (200 mg intravenously every three weeks) in combination with apatinib (250 mg orally once daily).”

direct quote[Methods, Statistical analysis; Data availability statement]

“SAS software (version 9.4) was used for all statistical analyses.”

WARNReviewer 2· 85% conf

Investigational drugs are not fully identified with manufacturer/source, while the companion diagnostic assay and software are adequately identified.

Evidence

direct quote[Methods, Procedures]

“camrelizumab (200 mg intravenously every three weeks) plus CAPOX (capecitabine 1000 mg/m2 orally twice daily on days 1-14 of each 21 day treatment cycle, and oxaliplatin 130 mg/m2 intravenously on day 1 of each cycle) for four to six cycles, followed by camrelizumab (200 mg intravenously every three weeks) in combination with apatinib (250 mg orally once daily).”

direct quote[Methods, Procedures]

direct quote[Methods, Statistical analysis]

“SAS software (version 9.4) was used for all statistical analyses.”

WARNReviewer 3· 85% conf

The investigational drugs are not fully identified with manufacturer/source, though the PD-L1 assay and SAS software are adequately described.

Evidence

direct quote[Methods, Procedures]

direct quote[Methods, Statistical analysis]

“SAS software (version 9.4) was used for all statistical analyses.”

direct quote[Methods, Procedures]

All primary and secondary analyses are named (log-rank, Cox, Clopper-Pearson). Exact p-values and 95% CIs are reported. No explicit test of proportional hazards is mentioned, but the use of stratified Cox models and large sample size is standard. No arithmetic errors detected.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityPASS

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical tests are well-specified, exact p-values and effect sizes with CIs are provided, software is identified, and data presentation meets clinical trial standards; assumptions verification is not explicitly tested but is acceptable given the large N and standard methods.

Evidence

direct quote[Methods, Statistical analysis]

“We compared overall survival and progression-free survival with the log rank test, stratified by Eastern Cooperative Oncology Group performance status (0 v 1), presence of peritoneal metastasis (yes v no), and PD-L1 expression status (positive v negative; overall population only).”

direct quote[Results, Efficacy in PD-L1 positive patients; Table 2]

“Overall survival was significantly prolonged with camre+CAPOX followed by camre+apa compared with CAPOX (hazard ratio 0.80, 95% CI 0.65 to 0.98; one sided P=0.02)”

direct quote[Methods, Statistical analysis]

“SAS software (version 9.4) was used for all statistical analyses.”

PASSReviewer 2· 90% conf

Statistical tests are named, effect sizes with CIs are reported, exact p-values are given, software is identified, and data presentation is appropriate for a clinical trial.

Evidence

direct quote[Methods, Statistical analysis]

direct quote[Results, Efficacy in PD-L1 positive patients]

“Overall survival was significantly prolonged with camre+CAPOX followed by camre+apa compared with CAPOX (hazard ratio 0.80, 95% CI 0.65 to 0.98; one sided P=0.02)”

direct quote[Methods, Statistical analysis]

“SAS software (version 9.4) was used for all statistical analyses.”

PASSReviewer 3· 90% conf

Statistical tests are well-described, exact p-values and effect sizes with CIs are reported, but assumptions such as proportional hazards are not explicitly verified.

Evidence

direct quote[Methods, Statistical analysis]

direct quote[Results, Efficacy in PD-L1 positive patients]

“Overall survival was significantly prolonged with camre+CAPOX followed by camre+apa compared with CAPOX (hazard ratio 0.80, 95% CI 0.65 to 0.98; one sided P=0.02)”

absence[Methods, Statistical analysis]

Proportional hazards assumption is not explicitly verified.

The data availability statement is concrete, naming a repository (Mendeley Data) with a URL. The data are openly accessible. However, the code is described as available in the supplemental file, which is not a version-controlled public repository with a permanent identifier, making it inadequate for code_sharing.

Sub-criteria

code sharingINADEQUATE

accession numbersN/A

repository depositADEQUATE

data availability statementADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 70% conf

A data availability statement with a concrete repository URL is provided, and the code is in the supplemental file; the code is not in a version-controlled repository, but data deposition meets the field standard for clinical trial data.

Evidence

direct quote[Data availability statement]

“The data underlying the findings in this paper are openly and publicly available and can be accessed here: https://data.mendeley.com/datasets/z22zyc2b2b/1”

direct quote[Data availability statement]

“The code used to analyse the data in the paper can be found in the supplemental file.”

WARNReviewer 2· 85% conf

A data availability statement with a repository URL is provided, and data are deposited in Mendeley Data, but the code is only available in the supplemental file without a persistent identifier.

Evidence

direct quote[Data availability statement]

“The data underlying the findings in this paper are openly and publicly available and can be accessed here: https://data.mendeley.com/datasets/z22zyc2b2b/1 .”

direct quote[Data availability statement]

“The code used to analyse the data in the paper can be found in the supplemental file.”

WARNReviewer 3· 85% conf

The data are openly available in a repository, but the analysis code is only provided in a supplemental file and not in a version-controlled public repository.

Evidence

direct quote[Data availability statement]

“The data underlying the findings in this paper are openly and publicly available and can be accessed here: https://data.mendeley.com/datasets/z22zyc2b2b/1”

direct quote[Data availability statement]

“The code used to analyse the data in the paper can be found in the supplemental file.”

The methods section is comprehensive. The trial is registered at ClinicalTrials.gov (NCT03813784). All pre-specified endpoints are reported, and negative results (no benefit of apatinib) are clearly presented. Limitations are acknowledged. Conclusions do not overreach. Funding and conflicts of interest are fully disclosed. The only gap is the lack of explicit mention of adherence to a reporting checklist (e.g., CONSORT), though the paper likely follows BMJ's requirements.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

Methods are detailed, trial is registered, outcomes are fully reported, limitations are discussed, conclusions are proportional, and funding/COI are disclosed. No reference to a specific reporting guideline (e.g., CONSORT) in the text.

Evidence

direct quote[Abstract, Methods]

“Trial registration ClinicalTrials.gov NCT03813784”

direct quote[Discussion, Strengths and limitations of this study]

“Several limitations should be acknowledged. Firstly, this open label trial used multiple therapeutic agents, and tumour responses were not assessed by a blinded independent central review committee.”

absence[Entire text]

No explicit mention of adherence to a reporting guideline (e.g., CONSORT) is found.

PASSReviewer 2· 90% conf

The manuscript is transparent: methods are detailed, the trial is registered, all outcomes are reported, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

direct quote[Abstract, Trial registration]

“ClinicalTrials.gov NCT03813784 (https://clinicaltrials.gov/ct2/show/NCT03813784)”

direct quote[Discussion, Strengths and limitations of this study]

direct quote[Competing interests]

“This study was funded by Jiangsu Hengrui Pharmaceuticals. ... LS reports receiving research grants from Beigene ...”

PASSReviewer 3· 90% conf

The manuscript is well-reported with a trial registration, detailed methods, proportional conclusions, and a limitations discussion, though it does not mention a specific reporting guideline.

Evidence

direct quote[Abstract]

“Trial registration ClinicalTrials.gov NCT03813784”

direct quote[Discussion, Strengths and limitations of this study]

absence[Methods]

No reporting guideline is mentioned.

8 copyedit issues flagged: mostly consistency, clarity.

Checked 26 references: 26 verified.

Reproducibility

1 data/code link checked; 1 live.

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Αlpha¹ Rigor Action ItemsFinal pass before journal submission

Post-publication audit: This paper is methodologically sound and reports a well-designed trial. An informed reader should note that the missing demographic details (weight, race/ethnicity), incomplete reagent identification, and code deposited only in a supplemental file are reporting gaps that do not affect the validity of the primary conclusions but would warrant a correction or clarification if the authors wish to meet contemporary best practices. No erratum is required for the core findings.

1.
HIGHrigor
Add manufacturer/source (vendor and lot number) for each investigational drug (camrelizumab, apatinib, capecitabine, oxaliplatin) in the Methods, Procedures section.
Current reporting omits reagent source, which is needed for reproducibility and meets key resource identification standards.
2.
HIGHrigor
Include the vendor, catalog number, and RRID for the E1L3N antibody used in PD-L1 testing in the Methods, Procedures section.
The antibody is a critical resource for biomarker assessment; missing identifiers hinder reproducibility.
3.
HIGHdata code
Deposit the analysis code in a version-controlled public repository (e.g., GitHub, Zenodo) and cite the DOI in the data availability statement, replacing the supplemental file reference.
Code in a supplemental file is not version-controlled and lacks a persistent identifier, which is a standard requirement for code sharing.
4.
HIGHreporting
Report weight and race/ethnicity in the baseline demographics table (Table 1) to provide complete biological variable and demographic information.
Missing weight and race/ethnicity limit the characterization of the study population, even if all participants are from a single country.
5.
MEDIUMreporting
Explicitly state adherence to the CONSORT reporting guideline in the Methods or Discussion section.
Clinical trials are expected to mention CONSORT; its absence is a minor reporting gap.
6.
MEDIUMstatistics
Add a brief statement in the Statistical Analysis section that the proportional hazards assumption was tested (e.g., using Schoenfeld residuals) or note that the method is robust to minor violations.
Cox models were used without explicit assumption verification, which is a standard reviewer concern.
7.
MEDIUMreporting
Provide a rationale for the open-label design in the Methods, Randomisation and masking section.
While the primary endpoint is objective, justifying the lack of blinding improves transparency.
8.
LOWcopyedit
Fix hyphenation: change 'One sided P=0.02' and 'one sided α' to 'one-sided' throughout the abstract and Methods.
Consistency in hyphenation improves readability and meets style standards.
9.
LOWcopyedit
Correct the parenthesis error in Results, paragraph 1: change '68 of (19.3%) 352 patients' to '68 (19.3%) of 352 patients'.
The extra parenthesis disrupts the intended format.
10.
LOWcopyedit
Use consistent abbreviation in Table 1 footnotes: change 'Camre+CAPOX followed by camre+apatinib' to 'Camre+CAPOX followed by camre+apa' to match the table header.
Inconsistent abbreviations between the table header and footnote may confuse readers.
11.
LOWcopyedit
Consider rephrasing the abstract intervention description to 'Camrelizumab plus CAPOX followed by camrelizumab-based maintenance versus CAPOX alone' for clarity.
The current phrasing could be misinterpreted as concurrent rather than sequential treatment.

Full text (67,387 chars)Analyzed: Jul 16, 2026

Read alongside